Reference desk / Entry
Dulaglutide
Also listed as: Trulicity
Read the scope first. Then use the note and questions to examine what the evidence can answer.
- Scoped product status
- Approved product
- Evidence label
- Randomized evidence
- Status as of
Reference fields
References for these fields are listed together in Sources.
- Product and use scope
- Trulicity: specified type 2 diabetes populations.
- Route context
- Subcutaneous injection.
- Mechanism
- GLP-1 receptor agonist fusion protein.
- Evidence
- Randomized studies.
- Limitations
- No weight-management indication.
- Safety
- Not recommended for severe gastroparesis.
A question worth making clear
Use a timeline to organize a report without asking the timeline to explain everything on it. If one event follows another, mark their order and identify where a causal explanation is proposed. Then ask what comparison would help distinguish that explanation from other possible accounts of the sequence. Earlier timing can be relevant to an argument without completing it. A shared sketch of the sequence should therefore leave room for uncertainty about why events occurred. That space helps readers discuss a proposed cause without presenting chronology itself as proof.
- What does the sequence establish about timing, and what does it leave unexplained?
- Where does the report move from describing an order to proposing a cause?
- Which comparison could help distinguish the proposed explanation from another account?
Sources
Each date below belongs to the supplied source record. The references support the entry as a group.
- TRULICITY
NLM · Checked